Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3844477 | 0.76 | DPP4 (0.69) | DPP4DPP8DPP7POLB | |
| SCHEMBL3844483 | 0.75 | KMT2A (0.47) | KMT2AMEN1ALDH1A1DPP4DPP8 | |
| SCHEMBL5999940 | 0.72 | DPP4 (0.55) | DPP4DPP8DPP7SMN1; SMN2 | |
| SCHEMBL5144573 | 0.72 | LMNA (0.33) | DPP4DPP8DPP7 | |
| SCHEMBL13698461 | 0.64 | ALDH1A1 (0.70) | KMT2AMEN1ALDH1A1POLBHTR7 | |
| SCHEMBL18701879 | 0.63 | LMNA (0.64) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13923614 | 0.63 | LMNA (0.67) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1464081 | 0.63 | LMNA (0.67) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL27896818 | 0.62 | LMNA (0.71) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6255120 | 0.62 | LMNA (0.63) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | KMT2A 2117/4885MEN1 537/4885ALDH1A1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.